This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.This is a randomized, double-blind, placebo-controlled, sequential dose escalation study to evaluate the safety, tolerability, maximum tolerance dose, physical affects and preliminary effectiveness of cidofovir in kidney transplant recipients with newly diagnosed BK virus-induced nephropathy (kidney disorder). Cidofovir VISTIDE is a marketed product for cytomegalovirus disease in HIV-infected patients.
Showing the most recent 10 out of 563 publications